Interleukin-30 Expression in Prostate Cancer and Its Draining Lymph Nodes Correlates with Advanced Grade and Stage

Purpose: The interleukin (IL)-27 cytokine subunit p28, also called IL-30, has been recognized as a novel immunoregulatory mediator endowed with its own functions. These are currently the subject of discussion in immunology, but completely unexplored in cancer biology. We set out to investigate the role of IL-30 in prostate carcinogenesis and its effects on human prostate cancer (hPCa) cells. Experimental Design: IL-30 expression, as visualized by immunohistochemistry and real-time reverse transcriptase PCR on prostate and draining lymph nodes from 125 patients with prostate cancer, was correlated with clinicopathologic data. IL-30 regulation of hPCa cell viability and expression of selected gene clusters was tested by flow cytometry and PCR array. Results: IL-30, absent in normal prostatic epithelia, was expressed by cancerous epithelia with Gleason ≥ 7% of 21.3% of prostate cancer stage I to III and 40.9% of prostate cancer stage IV. IL-30 expression by tumor infiltrating leukocytes (T-ILK) was higher in stage IV that in stage I to III prostate cancer (P = 0.0006) or in control tissue (P = 0.0011). IL-30 expression in prostate draining lymph nodes (LN)-ILK was higher in stage IV than in stage I to III prostate cancer (P = 0.0031) or in control nodes (P = 0.0023). The main IL-30 sources were identified as CD68+ macrophages, CD33+/CD11b+ myeloid cells, and CD14+ monocytes. In vitro, IL-30 stimulated proliferation of hPCa cells and also downregulated CCL16/LEC, TNFSF14/LIGHT, chemokine-like factor (CKLF), and particularly CKLF-like MARVEL transmembrane domain containing 3 (CMTM3) and greatly upregulated ChemR23/CMKLR. Conclusions: We provide the first evidence that IL-30 is implicated in prostate cancer progression because (i) its expression by prostate cancer or T- and LN-ILK correlates with advanced disease grade and stage; and (ii) IL-30 exerts protumor activity in hPCa cells. Clin Cancer Res; 20(3); 585–94. ©2013 AACR.

[1]  D. Taub,et al.  Differential G protein subunit expression by prostate cancer cells and their interaction with CXCR5 , 2013, Molecular Cancer.

[2]  Yuquan Wei,et al.  A protective role of IL-30 via STAT and ERK signaling pathways in macrophage-mediated inflammation. , 2013, Biochemical and biophysical research communications.

[3]  P. Allavena,et al.  Tumor-associated macrophages: functional diversity, clinical significance, and open questions , 2013, Seminars in Immunopathology.

[4]  B. Saha,et al.  IL-27 in tumor immunity and immunotherapy. , 2013, Trends in molecular medicine.

[5]  H. Seno,et al.  The role of CXCR3 and CXCR4 in colorectal cancer metastasis , 2013, International journal of cancer.

[6]  Christopher A Hunter,et al.  Interleukin-27: balancing protective and pathological immunity. , 2012, Immunity.

[7]  J. Scheller,et al.  An Interleukin-6 Receptor-dependent Molecular Switch Mediates Signal Transduction of the IL-27 Cytokine Subunit p28 (IL-30) via a gp130 Protein Receptor Homodimer* , 2012, The Journal of Biological Chemistry.

[8]  A. Trumpp,et al.  The evolving concept of cancer and metastasis stem cells , 2012, The Journal of cell biology.

[9]  V. Kuchroo,et al.  IL-12 family cytokines: immunological playmakers , 2012, Nature Immunology.

[10]  D. Gabrilovich,et al.  Molecular Pathways: Tumor-Infiltrating Myeloid Cells and Reactive Oxygen Species in Regulation of Tumor Microenvironment , 2012, Clinical Cancer Research.

[11]  H. Hermanns,et al.  Plasticity and cross-talk of interleukin 6-type cytokines. , 2012, Cytokine & growth factor reviews.

[12]  L. Mishra,et al.  Interleukin‐30: A novel antiinflammatory cytokine candidate for prevention and treatment of inflammatory cytokine‐induced liver injury , 2012, Hepatology.

[13]  D. Gabrilovich,et al.  Coordinated regulation of myeloid cells by tumours , 2012, Nature Reviews Immunology.

[14]  Xiao-Yan Du,et al.  Proteolytic Cleavage of Chemerin Protein Is Necessary for Activation to the Active Form, Chem157S, Which Functions as a Signaling Molecule in Glioblastoma* , 2011, The Journal of Biological Chemistry.

[15]  S. Fox,et al.  The Dawn of a Revolution in Personalized Lung Cancer Prevention , 2011, Cancer Prevention Research.

[16]  T. Yoshimura,et al.  Chemokine-like receptor 1 (CMKLR1) and chemokine (C-C motif) receptor-like 2 (CCRL2); two multifunctional receptors with unusual properties. , 2011, Experimental cell research.

[17]  P. Musiani,et al.  Androgen Deprivation Boosts Prostatic Infiltration of Cytotoxic and Regulatory T Lymphocytes and Has No Effect on Disease-Free Survival in Prostate Cancer Patients , 2010, Clinical Cancer Research.

[18]  C. Fielding,et al.  A role for IL-27p28 as an antagonist of gp130-mediated signaling , 2010, Nature Immunology.

[19]  M. Tagawa,et al.  The secreted form of p28 subunit of interleukin (IL)‐27 inhibits biological functions of IL‐27 and suppresses anti‐allogeneic immune responses , 2009, Immunology.

[20]  Wei Zheng,et al.  CMTM3, located at the critical tumor suppressor locus 16q22.1, is silenced by CpG methylation in carcinomas and inhibits tumor cell growth through inducing apoptosis. , 2009, Cancer research.

[21]  Z. Ou,et al.  Involvement of a Novel Chemokine Decoy Receptor CCX-CKR in Breast Cancer Growth, Metastasis and Patient Survival , 2009, Clinical Cancer Research.

[22]  P. Musiani,et al.  The Lack of Epithelial Interleukin-7 and BAFF/BLyS Gene Expression in Prostate Cancer as a Possible Mechanism of Tumor Escape from Immunosurveillance , 2009, Clinical Cancer Research.

[23]  Tingting Li,et al.  CMTM3 can affect the transcription activity of androgen receptor and inhibit the expression level of PSA in LNCaP cells. , 2008, Biochemical and biophysical research communications.

[24]  yang-xin fu,et al.  Targeting tumors with LIGHT to generate metastasis-clearing immunity. , 2008, Cytokine & growth factor reviews.

[25]  T. D'antuono,et al.  The prostate‐associated lymphoid tissue (PALT) is linked to the expression of homing chemokines CXCL13 and CCL21 , 2007, The Prostate.

[26]  E. Jaffee,et al.  Cancer immunologists and cancer biologists: why we didn't talk then but need to now. , 2007, Cancer research.

[27]  M. Batten,et al.  The biology and therapeutic potential of interleukin 27 , 2007, Journal of Molecular Medicine.

[28]  Xiaojing Ma,et al.  Regulation of IL-27 p28 gene expression in macrophages through MyD88- and interferon-γ–mediated pathways , 2007, The Journal of experimental medicine.

[29]  P. Lipponen,et al.  Expression of Ki-67, cyclin D1 and apoptosis markers correlated with survival in prostate cancer patients treated by radical prostatectomy. , 2006, Anticancer research.

[30]  J. Zhong,et al.  Characterization and expression profile of CMTM3/CKLFSF3. , 2006, Journal of biochemistry and molecular biology.

[31]  L. Hennighausen,et al.  Interleukin 27 negatively regulates the development of interleukin 17–producing T helper cells during chronic inflammation of the central nervous system , 2006, Nature Immunology.

[32]  Georg Bartsch,et al.  Interleukin‐6 regulation of prostate cancer cell growth , 2005, Journal of cellular biochemistry.

[33]  Chunxiao Wu,et al.  Molecular cloning and characterization of chemokine-like factor super family member 1 (CKLFSF1), a novel human gene with at least 23 alternative splicing isoforms in testis tissue. , 2004, The international journal of biochemistry & cell biology.

[34]  D. Bostwick,et al.  Intraepithelial and stromal lymphocytes in the normal human prostate , 2003, The Prostate.

[35]  T. Mcclanahan,et al.  IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4+ T cells. , 2002, Immunity.

[36]  L. Wang,et al.  Molecular cloning and characterization of chemokine-like factor 1 (CKLF1), a novel human cytokine with unique structure and potential chemotactic activity. , 2001, The Biochemical journal.

[37]  R. Young,et al.  Tumors of the Prostate Gland, Seminal Vesicles, Male Urethra, and Penis , 2000 .

[38]  H. Klocker,et al.  Immunohistochemical localization of interleukin‐6 and its receptor in benign, premalignant and malignant prostate tissue , 2000, The Journal of pathology.

[39]  B. Kwon,et al.  Isolation and characterization of LMC, a novel lymphocyte and monocyte chemoattractant human CC chemokine, with myelosuppressive activity. , 1998, Biochemical and biophysical research communications.

[40]  J. Montie.  Staging of prostate cancer , 1994, Cancer.

[41]  J. R. Landis,et al.  The measurement of observer agreement for categorical data. , 1977, Biometrics.

[42]  Y. Sekido,et al.  Hepatocyte Growth Factor Reduces Susceptibility to an Irreversible Epidermal Growth Factor Receptor Inhibitor in EGFR-T790M Mutant Lung Cancer , 2010 .

[43]  C. Ware,et al.  LIGHT, a new member of the TNF superfamily, and lymphotoxin alpha are ligands for herpesvirus entry mediator. , 1998, Immunity.

[44]  D. Bostwick,et al.  Staging of prostate cancer. , 1994, Seminars in surgical oncology.

[45]  W. Catalona,et al.  Tumors of the Prostate Gland , 1985 .

[46]  Gilmore Hr,et al.  Armed Forces Institute of Pathology. , 1968, Oral surgery, oral medicine, and oral pathology.

[47]  G. M. Gray,et al.  isolation and , 2022 .